Overview
- The peer-reviewed study published Wednesday, Oct. 7, 2026, reports that a subset of human microglia use trogocytosis, a selective 'nibbling' process, to remove intraneuronal alpha-synuclein aggregates without destroying the host neuron.
- Researchers showed the clearance depends on the microglial protein GPNMB and is tuned by the P2RY12 and CD22 signalling pathways, while the cytokine IL-10 acts as an autocrine brake that limits excessive immune activity.
- Findings come from human iPSC-derived co-cultures of dopamine neurons and microglia, single-cell RNA sequencing to define an activated microglial subtype, and CRISPR interference experiments that reduced GPNMB and impaired clearance.
- Human tissue analysis found elevated GPNMB in substantia nigra microglia from brains with alpha-synuclein pathology, strengthening the link between the lab model and human disease biology.
- Authors say the mechanism points to possible disease-modifying targets for Parkinson's but stress the need for animal validation and careful strategies to boost clearance without triggering damaging chronic inflammation.